Emily Engelhart

Title: Emily Engelhart: Innovator in Biopharmaceuticals

Introduction

Emily Engelhart is a prominent inventor based in Seattle, WA (US), known for her significant contributions to the field of biopharmaceuticals. With a total of two patents to her name, she has made remarkable advancements in the development of therapeutic proteins.

Latest Patents

Engelhart's latest patents include innovative variants of human interferon alpha-2 and interleukin 21. The first patent focuses on human interferon alpha-2 (IFNA2) variants that exhibit decreased or no detectable binding to the human interferon-alpha/beta receptor beta 2 (IFNAR2) compared to the wild-type human IFNA2 polypeptide. Additionally, this patent describes fusion proteins that covalently link an antibody or its fragment to the IFNA2 variant. The second patent presents interleukin 21 (IL-21) variants that either show decreased binding to the human IL-21 receptor (IL-21R) or increased stability compared to the wild-type human IL-21 polypeptide. This patent also includes fusion proteins that incorporate an antibody or its fragment bound to an IL-21 variant.

Career Highlights

Engelhart has established herself as a key figure in her field through her innovative research and development efforts. Her work at A-alpha Bio, Inc. has positioned her at the forefront of biopharmaceutical innovation, where she continues to explore new therapeutic avenues.

Collaborations

Engelhart collaborates with talented individuals such as Davis Goodnight and Ryan Swanson, contributing to a dynamic and innovative work environment.

Conclusion

Emily Engelhart's contributions to biopharmaceuticals through her patents and collaborative efforts highlight her role as a leading inventor in the industry. Her work continues to pave the way for advancements in therapeutic protein development.